Clinical Trial Update: Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating chidamide for relapsed or refractory peripheral T-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)

Snippet

Sponsor: Great Novel Therapeutics Biotech & Medicals Corporation | Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | Status: RECRUITING